PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Estradiol - Menopausal disorders
PAD Profile : Estradiol - Menopausal disorders
Keywords :
hormone replacement therapy, HRT, menopause, unopposed oestrogen, menopausal symptoms
Brand Names Include :
Elleste Solo, Estraderm MX patch, Estradot Patch, Evorel Patch, FemSeven Patch, Lenzetto spray, Oestrogel, Progynova, Progynova TS patch, Sandrena gel, Zumenon
Traffic Light Status
Status 1 of 5.
Status :
Green
Important
Preferred
Formulations :
- Tablets
Important Information :
Elleste Solo tablets - 1st line
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 5.
Status :
Green
Important
Formulations :
- Patches
Important Information :
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 3 of 5.
Status :
Green
Important
Formulations :
- Spray
Important Information :
Lenzetto spray. Caution with higher than licensed doses. Max supply of 20 containers per year to stay within licensed dose.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Status 4 of 5.
Status :
Green (see narrative)
Important
Formulations :
- Gel
Important Information :
Oestrogel is the preferred gel option. Sandrena is an alternative option.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 5 of 5.
Status :
Green (see narrative)
Important
Formulations :
- Tablets
Important Information :
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands APC has agreed a traffic light status and place in therapy for the treatments of menopausal disorders in line with the CKS recommenations:
06 April 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
LENZETTO - estradiol transdermal spray:
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Lenzetto® transdermal spray as a treatment option in the treatment of menopause
Lenzetto® will be considered GREEN on the traffic light system.
Associated BNF Codes
06. Endocrine System
06.04.01. Female sex hormones and their modulators